HC Wainwright Reaffirms “Buy” Rating for Jade Biosciences (NASDAQ:JBIO)

Jade Biosciences (NASDAQ:JBIO)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Thursday, MarketBeat reports. They currently have a $55.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 299.42% from the stock’s previous close.

JBIO has been the subject of several other research reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 price target on shares of Jade Biosciences in a research report on Tuesday, August 11th. Wedbush reaffirmed an “outperform” rating and set a $47.00 price target on shares of Jade Biosciences in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Jade Biosciences in a research report on Friday, September 11th. BTIG Research upped their price target on shares of Jade Biosciences from $74.00 to $77.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Finally, UBS Group assumed coverage on shares of Jade Biosciences in a research report on Monday, June 15th. They set a “buy” rating and a $45.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Jade Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $51.75.

Jade Biosciences Stock Performance

Shares of NASDAQ JBIO traded down $0.28 during midday trading on Thursday, hitting $13.77. 1,071,683 shares of the company’s stock traded hands, compared to its average volume of 752,015. Jade Biosciences has a 1 year low of $8.16 and a 1 year high of $28.00. The stock has a market capitalization of $875.77 million, a price-to-earnings ratio of -7.17 and a beta of 1.45. The firm has a fifty day moving average of $19.58 and a 200 day moving average of $19.74.

Jade Biosciences (NASDAQ:JBIO) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). On average, equities analysts anticipate that Jade Biosciences will post -2.89 earnings per share for the current year.

Institutional Investors Weigh In On Jade Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Engineers Gate Manager LP purchased a new stake in Jade Biosciences in the 2nd quarter worth approximately $503,000. Y Intercept Hong Kong Ltd purchased a new stake in Jade Biosciences in the 1st quarter worth approximately $353,000. Quantinno Capital Management LP increased its holdings in Jade Biosciences by 3.6% in the 1st quarter. Quantinno Capital Management LP now owns 30,551 shares of the company’s stock worth $429,000 after acquiring an additional 1,059 shares in the last quarter. Bank of America Corp DE increased its holdings in Jade Biosciences by 2.9% in the 1st quarter. Bank of America Corp DE now owns 38,598 shares of the company’s stock worth $542,000 after acquiring an additional 1,086 shares in the last quarter. Finally, Maven Securities LTD purchased a new stake in Jade Biosciences in the 2nd quarter worth approximately $1,111,000.

Jade Biosciences News Roundup

Here are the key news stories impacting Jade Biosciences this week:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and set a $55 price target, implying substantial upside from the recent trading level. The endorsement may support investor confidence in JBIO’s pipeline, although the target remains an analyst estimate. Benzinga reference
• Positive Sentiment: JADE301 produced encouraging preclinical results presented at EADV 2026. Jade said the half-life-extended anti-IFN-β antibody showed selective, high-affinity binding and greater functional potency than the dazukibart comparator in disease-relevant human cells. Jade Biosciences JADE301 preclinical data
• Positive Sentiment: In non-human primates, JADE301 had an approximately 25-day half-life, predictable distribution into muscle and good tolerability at all tested subcutaneous doses. The profile is intended to support infrequent dosing and could differentiate the program if confirmed clinically.
• Positive Sentiment: Jade expects to begin a Phase 1 healthy-volunteer trial in the fourth quarter of 2026, with interim data anticipated in the second half of 2027. This provides a defined near-term development milestone for investors.
• Neutral Sentiment: The company discussed JADE301’s program profile and preclinical data in a special call, transcript and slideshow, giving investors additional details but not yet providing human efficacy or safety results. JADE301 program discussion
• Negative Sentiment: The evidence remains preclinical, so the program still faces clinical-development risk. JADE301’s potential benefits, including its durability and potency, must be validated in human trials; the first interim clinical data are not expected until 2027.

About Jade Biosciences

Jade Biosciences, Inc (NASDAQ: JBIO) is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. The company uses antibody-based drug discovery and development approaches to pursue therapies intended to address significant unmet medical needs.

Jade Biosciences is advancing a pipeline of investigational programs and does not currently have commercially marketed products. Its work is centered on identifying and developing targeted therapies that may modulate biological pathways involved in autoimmune disease.

The company’s activities primarily consist of research, preclinical development and clinical evaluation of its drug candidates.